Related Experiment Videos

A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice

S G Khasar1, Y H Lin, A Martin

  • 1Department of Internal Medicine and Oral Surgery, National Institutes of Health/University of California, USA.

Neuron
|February 17, 2000
PubMed

Insights

Protein kinase C epsilon (PKCepsilon) plays a key role in pain signaling. Inhibiting PKCepsilon may offer a new strategy for pain therapeutics, as it reduces hyperalgesia without affecting normal pain sensation.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Current analgesics have limited efficacy, driving the search for novel pain therapy targets.
  • Protein kinase C (PKC) is known to enhance nociceptor function, but specific isozymes involved remain unidentified.

Purpose of the Study:

  • To identify the specific PKC isozymes involved in nociceptor function and hyperalgesia.
  • To investigate the potential of targeting PKCepsilon for pain treatment.

Main Methods:

  • Utilized PKCepsilon mutant mice to assess hyperalgesia responses.
  • Administered a PKCepsilon-selective inhibitor peptide in normal rats and cultured dorsal root ganglion (DRG) neurons.
  • Measured mechanical, thermal, and chemical hyperalgesia, as well as tetrodotoxin-resistant Na+ current (TTX-R I(Na)).

Main Results:

  • PKCepsilon mutant mice showed significantly reduced epinephrine-, acetic acid-, carrageenan-, and nerve growth factor- (NGF-) induced hyperalgesia.
  • Baseline nociceptive thresholds were unaffected in mutant mice.
  • A PKCepsilon-selective inhibitor peptide successfully inhibited hyperalgesia and epinephrine-induced enhancement of TTX-R I(Na) in DRG neurons.

Conclusions:

  • PKCepsilon is a critical regulator of nociceptor function and mediates various forms of hyperalgesia.
  • Targeting PKCepsilon with selective inhibitors presents a promising therapeutic strategy for managing pain and hyperalgesia.

Related Concept Videos